

SOLUBILITY DETERMINATION OF
CARBAMAZEPINE CO-CRYSTALS
IN ETHANOLIC SOLUTION AT
VARIOUS TEMPERATURE

NOOR ASHILA BINTI RAMLE

Master of Engineering (Chemical)

UNIVERSITI MALAYSIA PAHANG



SUPERVISOR'S DECLARATION

We hereby declare that we have checked this thesis and in our opinion, this thesis is adequate in terms of scope and quality for the award of the degree of Master of Engineering in Chemical.

(Supervisor's Signature)

Full Name : Dr. Syarifah Abd Rahim

Position : Senior Lecturer

Date :

A handwritten signature in black ink, appearing to be 'N. Anuar', written over a horizontal line.

(Co-supervisor's Signature)

Full Name : Dr. Nornizar Anuar

Position : Senior Lecturer

Date :



STUDENT'S DECLARATION

I hereby declare that the work in this thesis is based on my original work except for quotations and citations which have been duly acknowledged. I also declare that it has not been previously or concurrently submitted for any other degree at University Malaysia Pahang or any other institutions.

(Student's Signature)

Full Name : NOOR ASHILA BINTI RAMLE

ID Number : MKC13001

Date :

SOLUBILITY DETERMINATION OF CARBAMAZEPINE
CO-CRYSTALS IN ETHANOLIC SOLUTION
AT VARIOUS TEMPERATURE

NOOR ASHILA BINTI RAMLE

Thesis submitted in fulfillment of the requirements
for the award of the degree of
Master of Engineering (Chemical)

Faculty of Chemical Engineering and Natural Resources
UNIVERSITI MALAYSIA PAHANG

MAY 2018

DEDICATION

*This thesis were dedicated to my beloved husband Azim,
my precious daughter Raisya, my lovely parents and parents-in-law,
family, in laws and for those who made this possible.*

ACKNOWLEDGMENT

First and foremost, my gratitude and praises goes to ALLAH S.W.T, in whom I have put my trust and faith in, whom giving me strength and fortitude in facing all the problem and obstacles along the process of completing this research and fulfil my Master of Engineering (Chemical).

I would like to take this opportunity to express my profound gratitude to my research supervisors Dr Syarifah Abd Rahim, Dr Nornizar Anuar and Dr Omar El-Hadad for the noble guidance, valuable advices, constant support and providing a comfortable and fully equipped research environment all the way through the research process. Other than that, their patience, time, thoughts and understanding are highly appreciated.

I also would like to express my special appreciation to my husband Mohammad Azim, my daughter Nur Raisya Amsyar, parents, parents-in-law and siblings for their unconditional love, never ending supports and encouragements.

Finally, I would like to thank FKKSA laboratory their cooperation and guidance and University Malaysia Pahang for funding this research. For all my fellow colleagues, their help, support and understanding are really appreciated. All of their helped will always be remembered.

TABLE OF CONTENT

DECLARATION	
TITLE PAGE	
DEDICATION	ii
ACKNOWLEDGMENT	iii
ABSTRAK	iv
ABSTRACT	v
TABLE OF CONTENT	vi
LIST OF TABLES	xi
LIST OF FIGURES	xii
LIST OF SYMBOLS	xvi
LIST OF ABBREVIATIONS	xix
CHAPTER 1 INTRODUCTION	
1.1 Background of the Research	1
1.2 Problem Statement	4
1.3 Objectives of the Research	5
1.4 Scope of the Research	5
1.5 Research Significance	6
1.6 Thesis Layout	6
CHAPTER 2 LITERATURE REVIEW	
2.1 Introduction	8
2.2 Crystalline Solids: The Bonds and Intermolecular Interaction	8

2.3	Crystal System	12
2.4	Nucleation and Crystal Growth	15
2.4.1	Nucleation	16
2.4.2	Crystal Growth	19
2.4.2.1	Surface energy theory	20
2.4.2.2	Two-dimensional growth theory	22
2.4.2.3	Screw dislocation model	22
2.4.2.4	Birth and spread (B+S) model	23
2.5	Crystallization Engineering: Emergence of Co-Crystals Component	24
2.6	Pharmaceutical Co-Crystals	27
2.7	Formulation Methods of Co-Crystals	31
2.8	Selection of Co-Crystal Formers	34
2.9	Carbamazepine and its Co-Crystal Structures	37
2.10	Solubility of Crystal and Co-Crystal Components	39
2.11	Characterization Methods	41
2.11.1	Crystallographic Analysis using Powder X-ray Diffraction (PXRD) Technique	42
2.11.2	Fourier Transform Infrared (FTIR) Spectroscopy	43
2.11.3	Thermal Analysis using Differential Scanning Calorimetry (DSC)	43
2.11.4	Morphology Characterization using Optical Microscope	45
2.11.5	Solubility Analysis using High Performance Liquid Chromatography (HPLC)	46
2.12	Conclusion	48

CHAPTER 3 METHODOLOGY

3.1	Introduction	49
3.2	Flowchart of the Methodology	50
3.3	Materials	51
3.3.1	Carbamazepine	51
3.3.2	Co-crystal Formers (CCFs)	51
3.3.3	Solvent	52
3.4	Formation of Co-Crystal	52
3.5	Characterization of Carbamazepine Co-Crystals	53
3.5.1	Differential Scanning Calorimetry (DSC)	53
3.5.2	Powder X-ray Diffraction (PXRD)	54
3.5.3	Fourier Transform Infrared Spectroscopy (FTIR)	54
3.5.4	Optical Microscope	54
3.6	Solubility Studies of Carbamazepine, Co-crystal Formers and their Co-crystals	55
3.6.1	Sample Preparation	55
3.6.2	Dried Mass Gravimetric Method	55
3.7	Van't Hoff Solubility Plot	56
3.8	Solubility Enhancement Studies of CBZ Based High-Performance Liquid Chromatographic (HPLC) Analysis	57
3.8.1	Preparation for Calibration Curve	57
3.8.2	HPLC Sample Analysis	57
3.8.3	Solubility Data Determination	58

CHAPTER 4 RESULTS AND DISCUSSION

4.1	Introduction	59
4.2	Characterization of the Carbamazepine Co-Crystals	59

4.2.1	Differential Scanning Calorimetry (DSC)	59
4.2.2	Powder X-Ray Diffraction (PXRD)	62
4.2.3	Fourier Transform Infrared Spectroscopy (FTIR)	66
4.2.4	Optical Microscope	70
4.3	Solubility Determination of Carbamazepine (CBZ), Co-Crystal Formers (CCFs) and CBZ Co-Crystals	71
4.3.1	Solubility of Carbamazepine and Co-Crystal Formers	72
4.3.2	Solubility of Carbamazepine Co-Crystals	73
4.4	Assessment of Thermodynamic Properties of CBZ and CBZ Co-Crystals	77
4.4.1	Van't Hoff Solubility Plot	77
4.4.2	Activity Coefficient	82
4.5	Evaluation of CBZ Solubility Improvement	84
4.5.1	High-Performance Liquid Chromatography (HPLC) Analysis	84
4.5.1.1	Calibration Curves Determination	84
4.5.1.2	Carbamazepine and Co-Crystal Formers	85
4.5.1.3	Carbamazepine Solubility in CBZ-CCF Co-Crystals System	87
4.5.2	Solubility Ratio of CBZ and CBZ Co-Crystals	88
4.5.3	Comparison Between Dried Mass Gravimetric and HPLC Methods	90
4.6	Conclusion	93

CHAPTER 5 CONCLUSION AND RECOMMENDATIONS

5.1	Conclusion	95
5.1.1	Carbamazepine Co-Crystal Characterization	95
5.1.2	Solubility and Thermodynamic Properties Assessment of CBZ Co-Crystals	95

5.1.3	Improvement of CBZ Solubility	97
5.2	Recommendations	97
	REFERENCES	98
	APPENDIX A	106
	APPENDIX B	108
	APPENDIX C	109
	APPENDIX D	111
	APPENDIX E	115

LIST OF TABLES

Table 2.1	Types of bonding in solid materials	8
Table 2.2	Crystal system and Bravais lattices	14
Table 2.3	Example of pharmaceutical co-crystals system reported in literature	29
Table 2.4	List of carbamazepine co-crystals formulated based on stoichiometric crystallization screening methods (evaporation, dry and solvent drop grinding)	33
Table 3.1	List of CCFs, their melting point and functional groups	51
Table 3.2	HPLC setting variables	58
Table 4.1	Melting temperatures and enthalpy of fusion obtained from DSC analysis for CBZ, CCFs and four types of CBZ co-crystals formed	62
Table 4.2	Major peaks obtained from XRPD analysis for CBZ, CCFs and four type of CBZ solid crystals formed	66
Table 4.3	Optical microscopic image for CBZ crystal and CBZ co-crystals recrystallized by slow evaporation method at room temperature of 25 °C	70
Table 4.4	Melting temperatures and enthalpy of fusion obtained from DSC analysis for CBZ and CBZ co-crystal formed	77
Table 4.5	Enthalpy and entropy of dissolution process for CBZ and four types of CBZ co-crystals formed	81
Table 4.6	Solubility ratio, S in ethanol solvent system at 25 °C for four CBZ co-crystals formed	89
Table 4.7	Solubility ratio, S in ethanol solvent system at each temperature set for CBZ-CCF co-crystals formed	90

LIST OF FIGURES

Figure 2.1	Example of hydrogen bonds occur in NH ₃ and H ₂ O molecules	10
Figure 2.2	Schematic illustration of metallic bonding	11
Figure 2.3	Example of covalent bonding in a molecule of methane (CH ₄)	12
Figure 2.4	A three dimensional diagram of (a) a point lattice and (b) a unit cell show spatial dimensions and angles of the point lattice	13
Figure 2.5	Relationship between nucleation and crystal growth rate of crystallization process of melts	15
Figure 2.6	Free energy diagram for nucleation process shows the relationship between free energy and size of the nucleus	17
Figure 2.7	Crystal growth development of; (a) invariant and overlapping crystal (surface energy theory), (b) layer to layer growth unit absorbed on desired location on crystal surface (two-dimensional theory), (c) development of a spiral shape crystal growth (screw dislocation model) and (d) development of a polynuclear crystal growth by (birth and spread model).	21
Figure 2.8	Classification of solid forms	25
Figure 2.9	Typical hydrogen bonds in crystal engineering of co-crystals	26
Figure 2.10	Number of organic molecular co-crystal structures reported in CSD from 1988 to 2007.	27
Figure 2.11	Range of single crystalline forms that are possible for active pharmaceutical ingredient (API): (a) pure API; (b) polymorphs of pure API; (c) clathrate hydrate/solvate of API; (d) hydrates/solvate of API; (e) pharmaceutical salt and (f) co-crystals of API	28
Figure 2.12	Number of paper published on pharmaceutical co-crystals from 2006 to 2015	30
Figure 2.13	Schematic diagram of experimental techniques reported for co-crystallization screening in the literature	32
Figure 2.14	Schematic diagram of CBZ molecular structure	37
Figure 2.15	Illustration of (a) the formation of dimer between amide-amide (supramolecular homosynthon), (b) the structure of	

	CBZ dimer and (c) formation of dimer between amide-carboxylic acid (supramolecular heterosynthon)	38
Figure 2.16	Illustration of hydrogen bonding in CBZ-SAC form II co-crystal structure	39
Figure 2.17	Illustration of Bragg's diffraction phenomenon for a crystalline solid	43
Figure 2.18	Illustration of major peaks analyses in typical DSC curves	45
Figure 2.19	Schematic flow of HPLC analysis	46
Figure 2.20	Liquid chromatogram of a sample that consist three different compounds (A, B, C) with varies retention time	47
Figure 2.21	Agilent 1100 HPLC used in solubility study	48
Figure 3.1	Flowchart of Methodology	50
Figure 3.2	Ceramic vacuum filter setup apparatus used to separate the solid co-crystals formed	53
Figure 3.3	The slope and intercept of van;t Hoff solubility plot for an endothermic reaction	57
Figure 4.1	DSC profile show melting temperature and fusion enthalpy for CBZ crystal	60
Figure 4.2	DSC profile show melting temperature and fusion enthalpy for pure CBZ and CBZ co-crystals	61
Figure 4.3	X-ray diffraction pattern of pure CBZ crystal	63
Figure 4.4	Comparison graph of XRD pattern of; (a) CBZ, SUC and CBZ-SUC co-crystal and (b) CBZ, FUM and CBZ-FUM co-crystal	64
Figure 4.5	Comparison graph of XRD pattern of; (a) CBZ, NIC and CBZ-NIC co-crystal and (b) CBZ, SAC and CBZ-SAC co-crystal	65
Figure 4.6	FTIR spectra of pure CBZ (Form III) crystal	67
Figure 4.7	Comparison graph of FTIR spectra of (a)CBZ, NIC and CBZ-NIC co-crystal and (b) CBZ, SAC and CBZ-SAC co-crystal	68

Figure 4.8	Comparison graph of FTIR spectra of (a) CBZ, SUC and CBZ-SUC co-crystal and (b) CBZ, FUM and CBZ-FUM co-crystal	69
Figure 4.9	Solubility of pure components of CBZ and CCFs	72
Figure 4.10	Solubility of CBZ co-crystals	73
Figure 4.11	Crystal structure of CBZ-NIC co-crystal showing the intermolecular interaction of amide-amide homosynthon between two CBZ molecules.	75
Figure 4.12	Crystal structure of CBZ-SAC co-crystal showing the intermolecular interaction of amide-amide homosynthon between two CBZ molecules.	76
Figure 4.13	Crystal structure of CBZ-SUC co-crystal showing the intermolecular interaction of amide-acid heterosynthon between CBZ and SUC molecules	76
Figure 4.14	Crystal structure of CBZ-FUM co-crystal showing the intermolecular interaction of amide-acid heterosynthon between CBZ and FUM molecules	76
Figure 4.15	Van't Hoff solubility plot of CBZ and CBZ co-crystals; CBZ-NIC, CBZ-FUM, CBZ-SAC and CBZ-SUC in (a) ideal system and (b) experimental system..	78
Figure 4.16	Comparison of the van't Hoff plots between CBZ (experimental) with the ideal solution solubility showing negative deviation from ideality.	79
Figure 4.17	Comparison of the van't Hoff plots between CBZ-SUC (experimental) with the ideal solution solubility showing negative deviation from ideality.	80
Figure 4.18	Gibbs free energy plot of CBZ and CBZ co-crystals at different solubility temperature	82
Figure 4.19	Activity coefficients of CBZ and CBZ co-crystals	83
Figure 4.20	Calibration curve of CBZ for HPLC analysis	84
Figure 4.21	Calibration curve of NIC for HPLC analysis	85
Figure 4.22	Solubility of CBZ and CCFs at varies temperature measured using HPLC analysis	86
Figure 4.23	Concentration of CBZ component in CBZ-CCF co-crystals at varies temperature	87

Figure 4.24	Comparison between dried mass gravimetric and HPLC methods for (a) NIC (b) CBZ-NIC (c) SAC and (c) CBZ-SAC co-crystals	91
Figure 4.25	Comparison between dried mass gravimetric and HPLC methods for (a) SUC (b) CBZ-SUC (c) FUM and (c) CBZ-FUM co-crystals	92

LIST OF SYMBOLS

A	Surface area of the crystal
A, B	Complex temperature-dependent constant
a, b, c	Spatial dimensions of unit lattice
B	Number of nuclei
C	y-intercept
C_P	Heat capacity
c	Instantaneous solute concentration
c^*	Solute concentration at saturation
d	Interplanar spacing
dH/dt	Changes of heat flow over time
dT/dt	Heating rate
$f(T,t)$	Heat flow that is function of time at an absolute temperature
k_n	Rate constant
L	Characteristic dimension
M_T	Suspension density
m	Slope of linear equation
N	Number of nuclei per unit volume
n	Order of reflection
n, j, b	Empirical exponent
R	Gas constant (8.314 J/molK)
R_G	Crystal growth rate
R_{B+S}	Crystal growth rate based Birth and Spread model
R^2	Value of linear regression
r	Solute radius

r_c	Critical solute radius
S	Solubility ratio
S	Supersaturation ratio
T	Temperature
T_f	Temperature of melting or fusion
T_m	Temperature of melting
T_{sat}	Saturation temperature
t	Time
x	Mole fraction of solute
x_{ideal}	Mole fraction of solute in ideal system
Y, X	Intercepts on the plane axes
ΔG	Gibb's free energy
ΔG_s	Free energy change as the formation of unit surface
ΔG_v	Free energy change as the formation of unit volume
ΔH°	Enthalpy
ΔH_d	Enthalpy of dissolution
ΔH_f	Enthalpy of melting or fusion
ΔS°	Entropy
ΔS_d	Entropy of dissolution
°C	Degree Celsius
α, β, γ	Angles of the point lattice
α	Volume of the shape features
β	Area shape features
γ	Interfacial energy
γ	Activity coefficient

γ_x	Activity coefficient
λ	Wavelength of the incident x-ray beam
θ	Diffraction or scattering angle /angle
ρ	Crystal density
σ	Relative supersaturation
π	Radian

LIST OF ABBREVIATIONS

A, B, C	Lattice point at the centre of each pair of the cell lattice
ACN	Acetonitrile
ADHD	Attention-deficit hyperactivity disorder
API	Active pharmaceutical ingredient
BCF	Burton, Cabrera and Frank model
BCS	Biopharmaceutical classification system
B+S	Birth and spread
C	Base centered / Diamond
CBZ	Carbamazepine
CCFs	Co-crystal formers
CH ₂ Cl ₂	Dichloromethane
CH ₄	Methane
CO ₂	Carbon dioxide
COO ⁻	Carboxylic group
CSD	Crystal size distribution
DF	Dilution Factor
DSC	Diffraction scanning calorimetry
F	Face centered / Flourine molecule
FDA	Food and Drug Administration
Fe	Iron
FTIR	Fourier transforms infrared spectroscopy
FUM	Fumaric acid
GA	Glutaric acid
GRAS	Generally recognized as safe

Hg	Mercury
HPLC	High performance liquid chromatography
H ₂	Hydrogen gas
H ₂ O	Water
I	Body centered
KBr	Potassium bromide
MA	Maleic acid
Mg	Magnesium
MgO	Magnesium oxide
MW	Molecular weight
N	Nitrogen molecule
NaCl	Sodium chloride
NH ₂	Amidogen
NH ₃	Ammonia
NH ₃ ⁺	Amino group
NIC	Nicotinamide
NT	Nicotinamide
O	Oxygen molecule
P	Primitive cells
PXRD	Powder X-ray diffraction
RCS	Refrigerated cooling system
SAC	Saccharin
SCA	Succinic acid
SEM	Scanning electron microscope
SiO ₂	Silicon dioxide

SUC	Succinic acid
TA	Thermal analysis
TA	Thermogravimetric analyser
UV	Ultraviolet
W	Tungsten
XRD	X-ray diffraction

SOLUBILITY DETERMINATION OF CARBAMAZEPINE
CO-CRYSTALS IN ETHANOLIC SOLUTION
AT VARIOUS TEMPERATURE

NOOR ASHILA BINTI RAMLE

Thesis submitted in fulfillment of the requirements
for the award of the degree of
Master of Engineering (Chemical)

Faculty of Chemical Engineering and Natural Resources
UNIVERSITI MALAYSIA PAHANG

MAY 2018

ABSTRAK

Ko-penghabluran adalah salah satu teknik baru untuk reformasi hablur yang semakin diterima pakai kebelakangan ini apabila pendekatan tradisional seperti saringan garam tidak dapat dicapai bagi satu-satu molekul khususnya molekul yang mempunyai ionisasi lemah. Teknik ini membolehkan penggabungan dua atau lebih komponen organik dari bahan aktif farmaseutikal (API) dan komponen hablur bersama (CCF), dimana kedua-duanya hadir dalam bentuk pepejal di dalam keadaan persekitaran, digabung dalam struktur hablur yang sama tanpa memecahkan atau membentuk ikatan-kovalen yang baru. Ini seterusnya dapat menambah baik sifat-sifat fizikal dan kestabilan API tanpa mengubah integriti struktur hablur dan fungsi pengobatannya. Carbamazepine (CBZ) adalah sejenis dadah yang digunapakai sebagai ubat penenang dan penstabilan yang mempunyai sifat-sifat lemah dari segi kadar keterlarutan, kestabilan, polimorfisme dan keterbiosediaan yang menyumbang kepada masalah dos penggunaannya dalam merawat pesakit telah digunakan dalam kajian ini. Kajian ini memberi tumpuan kepada kebolehlarutan ko-hablur CBZ yang dihasilkan dari gabungan empat jenis CCFs iaitu nikotinamide (NIC), sakarin (SAC), asid suksinik (SUC) dan asid fumarik (FUM) pada suhu 25-55 °C. Kajian kebolehlarutan sistem ko-hablur merupakan salah satu faktor penting dalam meningkatkan dan membangunkan bidang farmaseutikal ko-penghabluran. Mesin kromatografi cecair berprestasi tinggi (HPLC) dan kaedah gravimetrik telah digunakan untuk menentukan keterlarutan setiap kristal komponen manakala peralatan analitikal (Pembelauan X-Ray hablur, pengimbas kalorimeter, pengimbas sinar-merah Fourier, dan mikroskop optik) digunakan untuk mengkaji ciri-ciri hablur dan ko-hablur yang terhasil. Eksperimen keterlarutan dijalankan dengan penambahan hablur ke dalam larutan etanol pada suhu yang berbeza (25-55 °C) dan dibiarkan selama 72 jam (sehingga mencapai keseimbangan). Hasil eksperimen dan maklumat terkumpul membuktikan bahawa kesemua hablur baru yang terhasil adalah komponen hablur baru yang dipercayai ko-hablur kepada CBZ dimana ia menunjukkan sifat-sifat yang berbeza seperti penurunan suhu takat lebur and bentuk morfologi yang berlainan. Hasil kajian juga menunjukkan profil kebolehlarutan semua komponen CBZ, CCFs dan ko-hablur CBZ meningkat selari dengan kadar peningkatan suhu. Situasi ini memenuhi 'Hukum Pertama Termodinamik' dimana haba yang dibekalkan menyumbang lebih banyak tenaga kepada sistem larutan dan secara tidak langsung memudahkan dan membantu proses pelarutan berlaku. Walau bagaimanapun, kebolehlarutan ko-hablur CBZ-NIC dan CBZ-FUM didapati lebih tinggi daripada hablur CBZ tulen, sementara kebolehlarutan ko-hablur CBZ-SUC lebih rendah daripada hablur CBZ tulen untuk julat suhu yang dikaji. Gaya yang berbeza diperolehi bagi ko-hablur CBZ-SAC, untuk suhu lebih rendah daripada 40 °C, kebolehlarutan hablur CBZ adalah lebih tinggi dan pada suhu yang lebih tinggi daripada 40 °C, ko-hablur CBZ-SAC mempunyai keterlarutan lebih tinggi daripada hablur CBZ. Plot kadar kelarutan van't Hoff pula menunjukkan sifat sisihan negatif untuk semua komponen hablur, ini menunjukkan kewujudan interaksi antara bahan larut dan pelarut dalam sistem tersebut. Hasil dapatan juga menunjukkan kepentingan proses pemilihan CCFs kerana setiap satu ko-hablur API-CCFs yang dihasilkan mempunyai sifat fisikokimia yang berbeza walaupun CCFs yang digunakan terdiri dari kumpulan berfungsi yang sama.

ABSTRACT

Co-crystallization is one of the new ways for crystal reformulation highlighted in recent years for weakly ionisable molecules when the traditional approaches, such as salt screening, cannot be achieved. This approach allows binding two or more organic components of an active pharmaceutical ingredient (API) and co-crystal former (CCF) that are, in their pure forms, solids under ambient conditions within one periodic crystalline lattice without breaking or making a new covalent bond. This, in turn, improves the API physicochemical properties and stability while maintaining its structural integrity and therapeutic functions. Carbamazepine (CBZ) is an anticonvulsant and mood-stabilizing drug known for its poor solubility, stability, polymorphism, and bioavailability, which causes problems in dosage consumption in treating patients, was used in this study. This study emphasis on a solubility study of CBZ co-crystals formed with nicotinamide (NIC), saccharin (SAC), succinic acid (SUC), and fumaric acid (FUM) as the CCFs at various temperatures (25-55 °C). Solubility study of the co-crystal system is an important factor in developing and improving the pharmaceutical co-crystallization pathway. High-Performance Liquid Chromatography (HPLC) and gravimetric methods were used to determine the solubility of each component while analytical equipment (X-Ray Powder Diffraction, Diffraction Scanning Calorimetry, Fourier Transform Infrared, and Optical Microscope) were used to characterize the solid crystals and co-crystals formed. The solubility experiment was conducted by the addition of a solid in ethanol solution at different temperatures (25-55 °C) and equilibrates at 72 hours. Based on the data collected, all the crystals formulated are characterized as new crystals believe to be CBZ co-crystals that show different physicochemical properties such as reduction of melting point and distinct morphology. The solubility profiles for all components of CBZ, CCFs and CBZ co-crystals shows the same trend where the solubility values increases as the temperature rises. This finding meets the First Law of Thermodynamics in which heat can facilitate the dissolution process by providing more energy to the system. In addition, the solubility of CBZ-NIC and CBZ-FUM co-crystals were found to be higher than that of pure CBZ crystal, while the solubility of the CBZ-SUC co-crystal was lower than that of pure CBZ crystal for the range of studied temperatures. A different trend was found for the CBZ-SAC co-crystal in which for temperatures lower than 40 °C, the solubility of CBZ crystal is higher, while at temperatures higher than 40 °C, the CBZ-SAC co-crystal has higher solubility than that of the CBZ crystal. The van't Hoff solubility plot indicates negative deviation behaviour for all crystal components, which shows the existence of an interaction between the solute and the solvent in the system. Findings of this study also show the significant of CCFs screening since different type of API-CCF co-crystals formulated produced different physicochemical properties even same functional group of CCFs is selected.

REFERENCES

- Aakeröy, C.B. (1997). Crystal engineering: strategies and architectures. *Acta Crystallographica. B53*: 569-586.
- Aakeröy, C.B., Beatty, A.M., Helfrich, B.A. and Nieuwenhuyzen, M. (2003). Do polymorphic compounds make a good cocrystallizing agents? A structural case study that demonstrates the importance of synthon flexibility. *Crystal Growth and Design. 3*: 159-165.
- Aakeröy, C.B., Fasulo, M.E. and Desper, J. (2007). Cocrystal or salt: does it really matter? *Molecular Pharmaceutics. 4*(3): 317-322.
- Aakeröy, C.B. and Salmon D.J. (2005). Building co-crystals with molecular sense and supramolecular sensibility. *Crystal Engineering Communication. 7*: 439-448.
- Abd Rahim, S. (2012). *Understanding and predicting the physicochemical properties and crystallisation behaviour of carbamazepine co-crystal*. Ph.D. Thesis. The University of Leeds, UK.
- Abd Rahim, S., Hammond, R.B., Sheikh, A.Y. and Roberts, K.J. (2013). A comparative assessment on the influence of different crystallization screening methodologies on the solid forms of carbamazepine co-crystals. *Crystal Engineering Communication. 15*: 3862-3873.
- Alhalaweh, A. (2012). *Pharmaceutical cocrystals (formation mechanisms, solubility behavior and solid-state properties)*. Ph.D. Thesis. Lulea University of Technology, Sweden.
- Almarsson, Ö., Peterson, M.L. and Zaworotko, M. (2012). The A to Z of pharmaceutical cocrystals: a decade of fast-moving new science and patents. *Pharmaceutical Patent Analyst. 1*(3): 313-327.
- Amidon, G.L., Lennernas, H., Shah, V.P. and Crison J.R. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. *Pharmaceutical Research. 12*(3): 413-420.
- Babu, N.J. and Nangia, A. (2011). Solubility advantage of amorphous drugs and pharmaceutical cocrystals. *Crystal Growth and Design. 11*: 2662-2679.
- Basavoju, S., Boström, D. and Velaga, S.P. (2006). Pharmaceutical cocrystal and salts of norfloxacin. *Crystal Growth and Design. 6*(12): 2699-2708.
- Bernus, I., Dickinson, R.G., Hooper, W.D. and Eadie, M.J. (1996). Dose-dependent metabolism of carbamazepine in humans. *Epilepsy Research. 24*: 163-172.

- Berry, D.J., and Steed, J.W. (2017). Pharmaceutical cocrystals, salts and multicomponent system; intermolecular interactions and property based design. *Advanced Drug Delivery Reviews*, <http://dx.doi.org/10.1016/j.addr.2017.03.003>
- Blagden, N., Matas, M.D., Gavan, P.T. and York, P. (2007). Crystal engineering of active pharmaceutical ingredients to improve solubility and dissolution rates. *Advanced Drug Delivery Reviews*. 59: 617-630.
- Blagden, N., Coles, S.J. and Berry, D.J. (2014). Pharmaceutical co-crystals – are we there yet? *Crystal Engineering Communication*. 16(26): 5753-5761.
- Blauch, D.N. (2014). Virtual chemistry experiment: Structure of solids (online). <http://www.chm.davidson.edu/vce/crystals/networksolids.html> (18 June 2014)
- Caliandro, R., Profio, G.D. and Nicolotti, O. (2013). Multivariate analysis of quaternary carbamazepine-saccharin mixtures by x-ray diffraction and infrared spectroscopy. *Journal of Pharmaceutical and Biomedical Analysis*. 78-79: 269-279.
- Callister, W.D. and Rethwisch, D.G. (2008). *Fundamentals of materials science and engineering*. Asia: John Wiley and Sons, Inc.
- Chandramouli, Y., Gandhimathi, R., Yasmeen, B.R., Vikram, A., Mahitha, B. and Imroz, S.M. (2012). Review on co-crystal as an approach with newer implications in pharmaceutical field. *International Journal of Medicine Chemistry and Analysis*. 2(2): 91-100.
- Chang, S. and Ho, A. (2018). *Effective techniques for managing trigeminal neuralgia, A volume in the Advances in Medical Diagnosis, Treatment and Care (AMDTC)*. USA: IGI Global.
- Chia, H.O. (2008). *Examination of the cooling crystallization kinetics and the solution chemistry of a model cocrystal system- carbamazepine:nicotinamide*. Msc. Thesis. University of Leeds, UK.
- Chieng, N., Hubert, M., Saville, D., Rades, T. and Aaltonen, J. (2009). Formation kinetics and stability of carbamazepine-nicotinamide cocrystals prepared by mechanical activation. *Crystal Growth and Design*. 9(5): 2377-2386.
- Childs, S.L., Stahly, G.P. and Park, A. (2007). The salt-cocrystal continuum: the influence of crystal structure on ionization state. *Molecular Pharmaceutics*. 4(3): 323-338.
- Childs, S.L., Rodríguez-Hornedo, N., Reddy, L.S., Jayasankar, A., Maheshwari, C., McCausland, L., Shipplett, R. and Stahly, B.C. (2008). Screening strategies based on solubility and solution composition generate pharmaceutically acceptable cocrystals of carbamazepine. *Crystal Engineering Communication*. 10(7): 856-864.

- Childs, S.L. and Zaworotko, M.J. (2009). The re-emergence of cocrystals: the crystal clear writing is on the wall introduction to virtual special issue on pharmaceutical cocrystals. *Crystal Growth and Design*. 9: 4208-4211.
- Cullity, B.D. (1978). *Elements of x-ray diffraction*. Massachusetts: Addison-Wesley Publishing Company, Inc.
- Dalplaz, A., Pavan, B., and Ferretti, V. (2017). Can pharmaceutical co-crystals provide an opportunity to modify the biological properties of drugs? *Drug Discovery Today*, 22(8): 1134-1138.
- Davey, R.J., Mullin, J.W., and Whiting, M.J.L. (1982). Habit modification of succinic acid crystals grown from different solvents. *Journal of Crystal Growth*. 58: 304-312.
- Desiraju, G.R. (1997). Crystal engineering: solid state supramolecular synthesis. *Solid State and Materials Science*. 2: 451-454.
- Di, L., Fish, P.V. and Mano, T. (2012). Bridging solubility between drug discovery and development. *Drug Discovery Today*. 17(9/10): 486-495.
- Espinosa-Lara, J., Guzman-Villanueva, D., Arenas-García, J.I., Herrer-Ruiz, D., Rivera-Islas, J., Román-Bravo, P., Morales-Rojas, H. and Höpfl, H. (2013). Cocrystals of active pharmaceutical ingredients- praziquantel in combination with oxalic, malonic, succinic, maleic, fumaric, glutaric, adipic, and pimelic acid. *Crystal Growth and Design*. 13: 169-185.
- Etter, M.C., Reutzel, S.M. and Choo, C.G. (1993). Self-organization of adenine and thymine in the solid state. *Journal of the American Chemical Society*. 115(10): 4411-4412.
- Fahlman, B.D. (2011). *Materials chemistry*. 2nd ed. Dordrecht, Netherlands: Springer.
- Fleischman, S.G., Kuduva, S.S., McMahon, J.A., Moulton, B., Walsh, R.D.B., Rodríguez-Hornedo, N. and Zaworotko, M.J. (2003). Crystal engineering of the composition of pharmaceutical phases: multiple-component crystalline solids involving carbamazepine. *Crystal Growth and Design*. 3(6): 909-919.
- Flicker, F., Eberle, V.A. and Betz, G. (2011). Variability in commercial carbamazepine samples - impact on drug release. *International Journal of Pharmaceutics*. 410: 99-106.
- Fukte, S.R., Wagh, M.P. and Rawat, S. (2014). Cofomer selection: an important tool in cocrystal formation. *International Journal of Pharmacy and Pharmaceutical Science*. 6(7): 9-14.
- Gagnière, E., Mangin, D., Puel, F., Rivoire, A., Monnier, O., Garcia, E. and Klein, J.P. (2009). Formation of co-crystals: kinetic and thermodynamic aspects. *Journal of Crystal Growth*. 311: 2689-2695.

- Grzesiak, A.L., Lang, M., Kim, K. and Matzger, A. J. (2003). Comparison of the four anhydrous polymorphs of carbamazepine and the crystal structure of form I. *Journal of Pharmaceutical Sciences*. 92(11): 2260-2271.
- Good, D.J. and Rodríguez-Hornedo, N. (2009). Solubility advantage of pharmaceutical cocrystals. *Crystal Growth and Design*. 9(5): 2252-2264.
- Götz, A.W. (2004). *Seminar of modern methods of theoretical chemistry: Crystal lattices*. Slide. University of Erlangen.
- Healy, A.M. (2017). Pharmaceutical solvates, hydrates and amorphous forms: a special emphasis on cocrystals. *Advanced Drug Delivery Reviews*. <http://dx.doi.org/10.1016/j.addr.2017.03.002>
- Hickey, A.J. and Ganderton, D. (2001). *Pharmaceutical process engineering*. USA: Marcel Dekker, Inc.
- Hickey, M.B., Peterson, M.L., Scoppettuolo, L.A., Morrisette, S.L., Vetter, A., Guzmán, H., Remenar, J.F., Zhang, Z., Tawa, M.D., Haley, S., Zaworotko, M.J. and Almarsson, Ö. (2007). Performance comparison of a co-crystal of carbamazepine with marketed product. *European Journal of Pharmaceutics and Biopharmaceutic*.67: 112-119.
- Hilfiker, R. (Ed). (2006). *Polymorphism in the pharmaceutical industry*. Weinheim, Germany: Wiley-VCH Verlag GmbH and Co.
- Höhne, G., Hemminger, W.F. and Flammersheim, H.J. (2003). *Differential scanning calorimetry* (2nd ed.). New York. Springer Science and Media.
- Jayasankar, A. (2008). *Understanding the mechanisms, thermodynamics and kinetics of cocrystallization to control phase transformations*. Ph.D. Thesis. The University of Michigan, US.
- Jayasankar, A., Reddy, L.S., Bethune, S.J. and Rodríguez-Hornedo, N. (2009). Role of cocrystal and solution chemistry on the formation and stability of cocrystals with different stoichiometry. *Crystal Growth and Design*. 9(2): 889-897.
- Jin, S., Wang, D., Huang, Y., Fang, H., Wang, T., Fu, P. and Ding, L. (2012). Hydrogen bonded supramolecular framework in organic acid-base adducts: Crystal structure of five cocrystals/salts assembled from 2-methylquinoline with monocarboxylic acid, dicarboxylic acid, and tricarboxylic acid. *Journal of Molecular Structure*. 1017: 51-59.
- Jones, W., Motherwell, W.D.S. and Trask, A.V. (2006). Pharmaceutical cocrystals: an emerging approach to physical property enhancement. *MRS Bulletin*. 31: 875-879.
- Khanam, J. (2007). *Pharmaceutical engineering: crystallization*. Ph.D. Thesis. University of Jadavpur, Kolkatta.

- Kothur, R.R. (2012). An outline of the crystal engineering of pharmaceutical co-crystals and applications: a review. *International Journal of Pharmaceutical research and Development*. 4(08): 084-092.
- Kumar, S. and Nanda, A. (2017). Pharmaceutical cocrystals: an overview. *Indian Journal of Pharmaceutical Science*. 79(6): 858-871.
- Kuminek, G., Cao, F., Rocha, A.B.O., Cardoso, S.G. and Rodríguez-Hornedo, N. (2016). Co-crystals to facilitate delivery of poorly soluble compounds beyond-rule-of-5. *Advanced Drug Delivery Reviews*. 101: 143-166.
- Liljeblad, A. (2015). *Evaluation of crystalline solid properties; experimental and theoretical comparison of polymorphs, solvates and co-crystals*. MSc Thesis. Chalmers University of Technology, Gothenburg, Sweden.
- Lin, H.L., Wu, T.K. and Lin, S.Y. (2014). Screening and characterization of cocrystal formation of metaxalone with short-chain dicarboxylic acids induced by solvent-assisted grinding approach. *Thermochimica Acta*. 575: 313-321.
- Liu, W., Dang, L., Black, S. and Wei, H. (2008). Solubility of carbamazepine (form III) in different solvents from (275 to 343) K. *Journal of Chemical Engineering Data*. 53: 2204-2206.
- Lynch, D.E., Latif, T., Smith, G., Byriel, K.A., Kennard, C.H.L. and Parsons, S. (1998). Molecular cocrystals of carboxylic acids xxxi: adducts of 2-aminopyrimidine and 3-amino-1,2,4-triazole with heterocyclic carboxylic acids. *Australian Journal of Chemistry*. 51: 403-408.
- Morissette, S.L., Almarsson, Ö., Peterson, M.L., Remenar, J.F., Read, M.J., Lemmo, A.V., Ellis, S., Cima, M.J. and Gardner, C.R. (2004). High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. *Advanced Drug Delivery Reviews*. 56: 275-300.
- Mota, F.L., Carneiro, A.P., Queimada, A.J., Pinho, S.P. and Macedo, E.A. (2009). Temperature and solvent effects in the solubility of some pharmaceutical compounds: measurements and modeling. *European Journal of Pharmaceutical Sciences*. 37:499-507.
- Mullin, J.W. (2001). *Crystallization*. 4thed. Oxford, United Kingdom: Butterworth Heinemann.
- Myerson, A.S. (Ed). (2002). *Handbook of industrial crystallization*. 2nd ed. Boston, Massachusetts: Butterworth Heinemann.
- Oberoi, L.M., Alexander, K.S. and Riga, A.T. (2005). Study of interaction between ibuprofen and nicotinamide using differential scanning calorimetry, spectroscopy, and microscopy and formulation of a fast-acting and possibly better ibuprofen suspension for osteoarthritis patients. *Journal of Pharmaceutical Sciences*. 94(1): 93-101.

- Othman, M.F. (2013). *A study on solution chemistry and crystallization behavior of L-alanine in the presence of additives*. MSc. Thesis. Univesiti Teknologi Mara, Malaysia.
- Pedireddi, V.R., Jones, W., Chorlton, A.P. and Docherty, R. (1996). Creation of crystalline supramolecular arrays: a comparison of co-crystal formation from solution and solid state grinding. *Chemical Communications*. 8: 987-988.
- Porter (III), W.W., Elie, S.C. and Matzger, A.J. (2008). Polymorphism in carbamazepine cocrystals. *Crystal Growth and Design*. 8(1): 14-16.
- Prasad, R.V., Rakesh, M.G., Jyotsna, R.M., Mangesh, S.T., Anita, P.S. and Mayur, P.K. (2012). Pharmaceutical cocrystallization: a review. *International Journal of Pharmaceutical and Chemical Science*. 1(3): 725-736.
- Rahman, M.J. (2011). *Structure of matter: crystalline and non-crystalline solids*. Lecture notes. Dhaka: Department of Physics, BUET.
- Remenar, J.F., Morissette, S.L., Peterson, M.L., Moulton, B., MacPhee, J.M., Guzmán, H.R. and Almarsson, O. (2003). Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids. *Journal of the American Chemical Society*. 125(28): 8456-8457.
- Rustichelli, C., Gamberini, G., Ferioli, V., Gamberini, M. C., Ficarra, R. and Tommasini, S. (2000). Solid-state study of polymorphic drugs: carbamazepine. *Journal of Pharmaceutical and Biomedical Analysis*. 23: 41-54.
- Savjani, K.T., Gajjar, A.K. and Savjani, J.K. (2012). Review articles. Drug solubility: importance and enhancement techniques. *International Scholarly Research Network*. 1-10.
- Schultheiss, N. and Newman, A. (2009). Pharmaceutical cocrystals and their physicochemical properties. *Crystal Growth and Design*. 9(6): 2950-2967.
- Shan, N. and Zaworotko, M.J. (2008). The role of cocrystals in pharmaceutical science. *Drug Discovery Today*. 13(9/10): 440-446.
- Sheikh, A.Y., Rahim, S.A., Hammond, R.B. and Roberts, K.J. (2009). Scalable solution cocrystallization: case of carbamazepine-nicotinamide I. *Crystal Engineering Communication*. 11: 501-509.
- Shikhar, A., Bommana, M.M., Gupta, S.S. and Squillante, E. (2011). Formulation development of Carbamazepine-Nicotinamide co-crystals complexed with γ -cyclodextrin using supercritical fluid process. *Journal of Supercritical Fluids*. 55: 1070-1078.
- Soares, F.L.F., and Carneiro, R.L. (2017). In-line monitoring of cocrystallization process and qualification of carbamazepine-nicotinamide cocrystak using raman spectroscopy and chemometric tools. *Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy*. 180: 1-8.

- Steed, J.W. (2013). The role of co-crystals in pharmaceutical design. *Trends in Pharmaceutical Sciences*. 34(3): 185-193.
- Stone, K. (updated). What is bioavailability? *Biotech Glossary* (online). <https://www.thebalance.com/what-is-bioavailability-4041140> (04 February 2017).
- Thakuria, R., Delori, A., Jones, W., Lipert, M.P., Roy, L. and Rodríguez-Hornedo, N. (2013). Pharmaceutical cocrystals and poorly soluble drugs. *International Journal of Pharmaceutics*. 453: 101-125.
- Thipparaboina, R., Kumar, D., Chavan, R.B. and Shastri, N.R. (2016). Multidrug co-crystals: towards the development of effective therapeutic hybrids. *Drug Discovery Today*. 21(3): 481-490.
- Tomaszewska, I., Karki, S., Shur, J., Price, R. and Fotaki, N. (2013). Pharmaceutical characterisation and evaluation of cocrystals: importance of in vitro dissolution conditions and type of conformer. *International Journal of Pharmaceutics*. 453: 380-388.
- Trask, A.V., Motherwell, W.D. and Jones, W. (2005). Pharmaceutical cocrystallization: engineering a remedy for caffeine hydration. *Crystal Growth and Design*. 5(3): 1013-1021.
- Voguri, R.S. (2010). *Co-crystallisation of α , ω -dicarboxylic acids with nicotinamide and isonicotinamide*. MSc. Thesis. University of Birmingham, UK.